Novartis' plea for Glivec patent denied by Indian high court

04/1/2013 | Reuters

Western drugmakers suffered a major blow after the Indian Supreme Court rejected Novartis' petition for patent protection for its cancer treatment Glivec. The landmark ruling sets a reference point for other intellectual-property disputes in the country and is likely to affect many other drugmakers and their brand-name treatments, analysts say.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX